September 29, 2012 at 10:40 AM EDT
The Week in Review: China Kanghui Bought by Medtronic for $816 Million
China Kanghui Holdings will be acquired by fellow medical device maker Medtronic for $816 million; China Nuokang Bio-Pharma accepted a go-private offer that values the company at $114 million; Medicago, a Canadian vaccines company, has out-licensed China rights to its pandemic and seasonal flu vaccines to cigarette maker Philip Morris Products in a $12 million deal; BGI of Shenzhen will build a next generation sequencing facility in Singapore in a diagnostics partnership with INEX Innovations; Novo Nordisk officially opened a new $100 million R&D center in Beijing; Neuralstem was granted SFDA approval to begin a clinical trial in China of its spinal cord stem cell product as a treatment for stroke; and the BayHelix Group together with Elsevier Business Intelligence handed out four awards for innovation in China pharma development. More details…. Stock Symbols: (NYSE: KH) (NYSE: MDT) (NSDQ: NKBP) (TSX: MDG) (NYSE: NVO) (NYSE: CUR) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here